Adam Raben

ORCID: 0009-0002-7148-2070

Also affiliated with Medical Oncology Hematology Consultants

MedicinePhysics and Astronomy

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 1 paper. Top paper: “Phase II trial of adjuvant de-escalated radiation + adjuvant nivolumab for intermediate-high risk P16+ oropharynx cancer.”.

Phase II trial of adjuvant de-escalated radiation + adjuvant nivolumab for intermediate-high risk P16+ oropharynx cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.6014

N/A

0DataRank · unranked

1 citations

Dan P. Zandberg, Adam Raben, Shaum Sridharan, Mark Kubik, José P. Zevallos +6 more